Phase 2 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are planned to receive immunotherapy after surgery
- People who have no signs of cancer that has spread to distant parts of the body, based on physical examination and imaging scans
- People who had no signs of cancer in their lymph nodes before a sentinel lymph node biopsy (a procedure to check nearby lymph nodes)
- People whose sentinel lymph node biopsy confirmed melanoma with at least one high-risk feature — such as cancer breaking through the lymph node's outer layer, a tumour deposit of 0.5mm or larger in the node, two or more affected lymph nodes, or cancer found in blood or lymph vessels near the original tumour
- People who have provided written consent to take part in the trial
- People with a general health and activity level rated 3 or below on a standard medical scale (meaning some self-care may be limited but the person is not completely unable to care for themselves — confirm with trial site)
- People with a life expectancy of more than 6 months
- People who are capable of becoming pregnant and are using adequate contraception
- People who are able to attend follow-up appointments
Who may not be able to join:
- People who have had a full removal of all lymph nodes in the affected area (complete lymph node dissection)
- People whose cancer has already spread to distant parts of the body
- People who have previously had radiation therapy to the same lymph node area being considered for treatment in this trial, where the new treatment would overlap with tissue that was already irradiated
- People who are currently pregnant
- People who are unable to provide their own informed consent, anyone under the age of adulthood, pregnant women, and prisoners
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Devarati Mitra, M.D. Anderson Cancer Center
Phone: 713-563-1339
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time to regional nodal recurrence
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.